FDA approves Inqovi for acute myeloid leukemia
· Medical Xpressby Lori Solomon
edited by Sadie Harley, reviewed by Andrew Zinin
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Lead Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
reputable news agency
proofread
The GIST Add as preferred source
The U.S. Food and Drug Administration has approved Taiho Oncology's Inqovi (decitabine and cedazuridine) plus venetoclax for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older or who are ineligible for intensive induction chemotherapy.
The combination of Inqovi plus venetoclax is the first and only oral hypomethylating regimen approved for this population, offering an alternative to parenteral hypomethylating agent-based regimens that require frequent clinic visits.
The approval was based on results from the Phase II ASCERTAIN-V study, which showed that the combination treatment resulted in 42 patients achieving a complete remission (CR; 41.6%), with a median time to CR of two months. The median duration of CR was not reached.
Serious adverse reactions occurred in 82% of patients who received the combination treatment, including serious adverse reactions of febrile neutropenia (31%), sepsis (22%), pneumonia (15%), bacterial or viral infection (10%), hemorrhage (9%), and dyspnea (6%). Fatal adverse reactions occurred in 8% of patients.
"This approval marks an important step forward in expanding how treatment can be delivered for this patient population, offering an all‑oral option that can potentially reduce the overall treatment burden associated with receiving treatment in hospitals or infusion centers," Harold Keer, M.D., Ph.D., the chief medical officer at Taiho Oncology, said in a statement.
"We believe this approach has the potential to make a meaningful impact for patients and caregivers."
More information
Key medical concepts
Acute Myeloid LeukemiaFebrile Neutropenia
Clinical categories
Oncology Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Copyright © 2026 HealthDay. All rights reserved.
Citation: FDA approves Inqovi for acute myeloid leukemia (2026, May 25) retrieved 25 May 2026 from https://medicalxpress.com/news/2026-05-fda-inqovi-acute-myeloid-leukemia.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.